A phase 1 dose-escalating trial evaluating CD70 inhibition in combination with hypomethylating therapy results in the elimination of leukemia stem cells and achieves clinical activity in untreated patients with acute myeloid leukemia.
- Carsten Riether
- Thomas Pabst
- Adrian F. Ochsenbein